Synmosa Biopharma Cash Flow Conversion Efficiency
Synmosa Biopharma cash flow conversion efficiency. Based on the latest financial reports, Synmosa Biopharma (4114) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$185.72 Million ≈ $5.85 Million USD) by net assets (NT$10.10 Billion ≈ $318.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Synmosa Biopharma (2015–2025)
Cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2025. This chart illustrates how Synmosa Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 4114 share price today for real-time trading data and today's change.
Synmosa Biopharma Cash Flow Conversion Ratio Explained
Synmosa Biopharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Synmosa Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synmosa Biopharma ranked by their cash flow conversion efficiency. Also see Synmosa Biopharma (4114) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
0.002x |
|
ENTERA BIO IS-0000769
F:5DT
|
-0.477x |
|
Zhengzhou J and T Hi Tech Co
SHE:300845
|
0.021x |
|
Petpal Pet Nutrition Technology Co Ltd
SHE:300673
|
0.013x |
|
Wuhan Hiteck Biological Pharma Co Ltd
SHE:300683
|
-0.008x |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
0.008x |
|
Kaili Catalyst & New Materials Co. Ltd. A
SHG:688269
|
0.008x |
|
BlueLinx Holdings Inc
NYSE:BXC
|
-0.093x |
Annual Cash Flow Conversion Efficiency for Synmosa Biopharma (2015–2025)
The table below shows the annual cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2025. Review 4114 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.10 Billion ≈ $318.18 Million |
NT$411.57 Million ≈ $12.97 Million |
0.041x | -56.15% |
| 2024-12-31 | NT$8.40 Billion ≈ $264.61 Million |
NT$780.62 Million ≈ $24.59 Million |
0.093x | +47.08% |
| 2023-12-31 | NT$8.10 Billion ≈ $255.22 Million |
NT$511.93 Million ≈ $16.13 Million |
0.063x | -33.33% |
| 2022-12-31 | NT$6.65 Billion ≈ $209.47 Million |
NT$630.25 Million ≈ $19.86 Million |
0.095x | +30.05% |
| 2021-12-31 | NT$6.10 Billion ≈ $192.04 Million |
NT$444.29 Million ≈ $14.00 Million |
0.073x | +70.61% |
| 2020-12-31 | NT$5.95 Billion ≈ $187.60 Million |
NT$254.40 Million ≈ $8.02 Million |
0.043x | +558.15% |
| 2019-12-31 | NT$4.81 Billion ≈ $151.63 Million |
NT$-44.88 Million ≈ $-1.41 Million |
-0.009x | -361.48% |
| 2018-12-31 | NT$4.49 Billion ≈ $141.31 Million |
NT$16.00 Million ≈ $503.96K |
0.004x | +372.28% |
| 2017-12-31 | NT$3.97 Billion ≈ $124.93 Million |
NT$-5.19 Million ≈ $-163.64K |
-0.001x | -102.41% |
| 2016-12-31 | NT$4.35 Billion ≈ $137.14 Million |
NT$236.48 Million ≈ $7.45 Million |
0.054x | +593.84% |
| 2015-12-31 | NT$3.01 Billion ≈ $94.96 Million |
NT$23.60 Million ≈ $743.59K |
0.008x | -- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more